DBV Technologies SA Sponsored ADR
(NASDAQ : DBVT)

( )
DBVT After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-1.94%88.651.3%$796.69m
AMGNAmgen Inc.
-0.76%185.501.2%$630.51m
GILDGilead Sciences, Inc.
-2.14%65.550.9%$497.34m
BIIBBiogen Inc.
-4.17%321.171.3%$426.56m
ILMNIllumina, Inc.
-1.77%296.883.5%$314.34m
REGNRegeneron Pharmaceuticals, Inc.
-0.92%418.622.6%$301.49m
VRTXVertex Pharmaceuticals Incorporated
-2.55%183.061.9%$262.15m
ALXNAlexion Pharmaceuticals, Inc.
-1.76%127.552.0%$232.43m
SRPTSarepta Therapeutics, Inc.
-2.87%136.5415.4%$150.79m
AAgilent Technologies, Inc.
-0.83%77.911.6%$143.97m
EXASExact Sciences Corporation
-0.42%83.2825.3%$128.91m
INCYIncyte Corporation
-0.49%83.332.5%$114.75m
ARRYArray BioPharma Inc.
-1.99%22.718.2%$107.63m
EXELExelixis, Inc.
-0.09%21.226.4%$83.96m
NBIXNeurocrine Biosciences, Inc.
-2.58%77.315.1%$78.49m

Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company, which deals with conducting of research and development of epicutaneous immunotherapy products. It focuses on developing a novel technology platform called Viaskin, which is an electrostatic patch that offers a convenient, self-administered, non-invasive immunotherapy to patients. The company has designed two products candidates: Viaskin Peanut and Viaskin Milk. DBV Technologies was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.